Examination about the susceptibility of the FTO gene single nucleotide polymorphism for leukopenia by the thiopurine in the inflammatory bowel disease.

Examination about the susceptibility of the FTO gene single nucleotide polymorphism for leukopenia by the thiopurine in the inflammatory bowel disease. - AZAFTO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024635

Enrollment

Registered

2016-11-03

Start date

2017-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age is one younger than 65 years 16 years old or older (2) The patients who had a diagnosis of Crohn's disease or ulcerative colitis (3) It is among internal use or internal use due to begin one with thiopurine preparation (azathioprine, 6-mercaptopurine) now.

Exclusion criteria

Exclusion criteria: (1) One in this hospital without the plan of the examination of drawing blood. (2) In the one that has already taken thiopurine preparation, thiopurine preparation is internal use start and the that there are not blood data when it was.

Design outcomes

Primary

Measure	Time frame
If it is found that gene single nucleotide polymorphism (SNPs) of FTO and RUNX1 is one of the predictors of the adverse event with the thiopurine preparation by this study in addition to NUDT15, safety will be secured for treatment preferences of the inflammatory bowel disease by clinical application.	—

Countries

Japan

Contacts

Public ContactHirotsugu Imaeda

Shiga University of Medical Science Division of Gastroenterology, Department of Medicine

imaeda@belle.shiga-med.ac.jp077-548-2217

Outcome results